Showing 2901-2910 of 5771 results for "".
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLs in the European Unionhttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols-in-the-european-union/2482610/Bausch + Lomb announced the commercial launch of the enVista Aspire monofocal and toric IOLs in the European Union after receiving a CE Mark late last year. According to B+L, enVista Aspire combines 'intermediate optimized' optics, which are designed for a broader dept
- Dry Eye Institute Launches 'DEI On Demand' and Kicks Off Inaugural Road Eventhttps://modernod.com/news/dry-eye-institute-launches-dei-on-demand-and-kicks-off-inaugural-road-event/2482605/The Dry Eye Institute (DEI), an educational program for optometrists and ophthalmologists specializing in advanced dry eye care, has announced that for the first time, the institute’s curriculum is now available online through 'DEI On Demand.' DEI also announced that
- Rayner Introduces Redesigned RayTrace for Quicker and Clearer IOL Calculationshttps://modernod.com/news/rayner-introduces-redesigned-raytrace-for-quicker-and-clearer-iol-calculations/2482604/Rayner announced the launch of its redesigned online premium IOL calculator, RayTrace. One of the first online IOL calculation tools, RayTrace has been used by surgeons globally since 2008 for the accuracy of its premium IOL (toric, multifocal and supplementary) calculations,
- Aviceda Therapeutics Raises $207.5 Million to Advance Lead Program AVD-104 for Geographic Atrophy into Phase 3 Testinghttps://modernod.com/news/aviceda-therapeutics-raises-2075-million-to-advance-lead-program-avd-104-for-geographic-atrophy-into-phase-3-testing/2482603/Aviceda Therapeutics announced the closing of a $207.5 million Series C financing to propel the company’s pivotal phase 3 clinical trial for AVD-104, a treatment candidate for geographic atrophy
- Atsena Therapeutics Initiates Part B of Phase 1/2 Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-initiates-part-b-of-phase-12-clinical-trial-evaluating-gene-therapy-atsn-201-to-treat-x-linked-retinoschisis/2482602/Atsena Therapeutics announced the initiation of Part B of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s n
- Topcon Healthcare Appoints Christian Odaker as Chief Technology Officerhttps://modernod.com/news/topcon-healthcare-appoints-christian-odaker-as-chief-technology-officer/2482599/Topcon Healthcare announced the appointment of Christian Odaker, PhD, to the role of Chief Technology Officer (CTO). Dr. Odaker willsupport the company's 'Healthcare from the Eye' initiative, which leverages AI-powered disease detection and management using da
- Lumibird Medical Rebrands its Japanese Subsidiaryhttps://modernod.com/news/lumibird-medical-rebrands-its-japanese-subsidiary/2482598/Lumibird Medical has announced the rebranding of its Japanese subsidiary. Formerly known as Ellex Japan, the company will now operate under the name Lumibird Medical Japan, effective immediately. Founded in Osaka in 2003, the subsidiary has grown over the past two decades,&nbs
- Valo Health Suspends Development of DR Drug Candidate After Phase 2 Study Resultshttps://modernod.com/news/valo-health-suspends-development-of-dr-drug-candidate-after-phase-2-study-results/2482594/Valo Health announced topline data from its phase 2 SPECTRA study of OPL-0401 in patients with diabetic retinopathy (DR). The study did not meet its primary or secondary endpoints based on the analysis in the prede&sh
- Galimedix Therapeutics Initiates Phase 2 Study with GAL-101 Eye Drops in Dry AMDhttps://modernod.com/news/galimedix-therapeutics-initiates-phase-2-study-with-gal-101-eye-drops-in-dry-amd/2482590/Galimedix Therapeutics announced the initiation of a phase 2 study (eDREAM;
- Glaukos Submits New Drug Application to FDA for Epioxahttps://modernod.com/news/glaukos-submits-new-drug-application-to-fda-for-epioxa/2482589/Glaukos announced it has submitted a new drug application (NDA) to the FDA for Epioxa (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus. “The NDA submission for Epioxa represents an important milestone for our company